Does Rallies show 13F holders for SPRY?

Yes. Rallies tracks hedge fund and 13F ownership data for SPRY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SPRY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SPRY. It does not provide personalized investment advice.

SPRY (ARS Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is a publicly traded Healthcare sector company. As of May 20, 2026, SPRY trades at $7.83 with a market cap of $724.91M and a P/E ratio of -3.83. SPRY moved +8.65% today. Year to date, SPRY is -28.90%; over the trailing twelve months it is -45.57%. Its 52-week range spans $6.66 to $18.90. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces SPRY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SPRY stock?

Hedge funds tracked by Rallies that own SPRY include Orbimed Advisors, Third Point, Duquesne Family, Centerbook Partners, and Sculptor Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ARS Pharmaceuticals, Inc. Common Stock.

SPRY Key Metrics

Key financial metrics for SPRY
Metric	Value
Price	$7.83
Market Cap	$724.91M
P/E Ratio	-3.83
EPS	$-2.00
Dividend Yield	0.00%
52-Week High	$18.90
52-Week Low	$6.66
Volume	1.40M
Avg Volume	0
Revenue (TTM)	$98.99M
Net Income	$-197.98M
Gross Margin	0.00%

Top Hedge Funds Holding SPRY

Orbimed Advisors holds 8.29M shares of SPRY, changed +0.00% as of Mar 31, 2026.
Third Point holds 1.00M shares of SPRY, changed +79.78% as of Mar 31, 2026.
Duquesne Family holds 536.90K shares of SPRY, changed +0.00% as of Sep 30, 2024.
Centerbook Partners holds 291.18K shares of SPRY, changed -48.77% as of Mar 31, 2026.
Sculptor Capital holds 77.10K shares of SPRY, changed +0.00% as of Sep 30, 2025.

Latest SPRY News

ARS Pharmaceuticals to Remove CVS Prior Authorizations by July 1 Following 3x Neffy Volume Surge — May 16, 2026
Ars Pharmaceuticals Sees Neffy Prescriptions Triple and Revenue Double in Q1 — May 15, 2026
ARS Pharmaceuticals Q1 Loss of $0.61, Revenue Beats at $22.68M with $17.5M Neffy Sales — May 15, 2026
ARS Pharmaceuticals Appoints Donn Casale to Lead Neffy Expansion and CSU Entry — May 13, 2026
ARS Pharmaceuticals Forecasts 180.8% EPS Drop and 70.3% Revenue Decline — Mar 2, 2026

Recent SPRY Insider Trades

Dorsey Brian sold 21.83K (~$190.05K) on Nov 13, 2025.
Chakma Justin sold 30.00K (~$267.36K) on Nov 12, 2025.
Chakma Justin sold 136.38K (~$1.21M) on Nov 12, 2025.

SPRY Analyst Consensus

3 analysts cover SPRY: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.

Common questions about SPRY

Who owns SPRY stock?: Hedge funds tracked by Rallies that own SPRY include Orbimed Advisors, Third Point, Duquesne Family, Centerbook Partners, and Sculptor Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ARS Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for SPRY?: Yes. Rallies tracks hedge fund and 13F ownership data for SPRY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SPRY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SPRY. It does not provide personalized investment advice.